Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Electric Vehicles and Future Mobility vs Nuvation Bio Inc. Class A Common Stock — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $27.56 (market cap $74.06M), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Nuvation Bio Inc. Class A Common Stock is far larger — about 23.1× KraneShares Electric Vehicles and Future Mobility's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 46 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| KARS | NUVB | |
|---|---|---|
Market Cap | $74.06M | $1.71B |
Volume | 2,546 | 5,448,712 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $9.54 |
52-Week Low | $27.25 | $3.41 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $1.30B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
